A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse
Phase of Trial: Phase II
Latest Information Update: 09 Dec 2018
At a glance
- Drugs Glasdegib (Primary)
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 31 May 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 31 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2020.
- 14 Sep 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.